Begin main content

naltrexone hydrochloride and bupropion hydrochloride

Last Updated: May 16, 2019
Result type: Reports
Project Number: SR0610-000
Product Line: Common Drug Review

Generic Name: naltrexone hydrochloride and bupropion hydrochloride

Brand Name: Contrave

Manufacturer: Bausch Health, Canada Inc.

Indications: Chronic weight management in adults

Manufacturer Requested Reimbursement Criteria1: Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: · 30 kg/m2 or greater (obese) or· 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)

Project Status: Active

Biosimilar: No

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedMarch 28, 2019
Patient group input closedMay 17, 2019
Patient input summary sent for review to patient input groups-
Patient group comments on input summary closed-
Submission receivedMay 01, 2019
Submission accepted for reviewMay 15, 2019
Review initiatedMay 16, 2019
Draft CADTH review report(s) sent to applicantJuly 31, 2019
Comments from applicant on draft CADTH review report(s) receivedAugust 12, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicantSeptember 06, 2019
Canadian Drug Expert Committee (CDEC) meetingSeptember 18, 2019
CDEC recommendation sent to applicant and drug plansOctober 02, 2019